Alaunos Therapeutics to Present at the Jefferies Healthcare Conference
Alaunos Therapeutics (TCRT) announces its participation in the Jefferies 2022 Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alaunos Therapeutics (TCRT) announces its participation in the Jefferies 2022 Global Healthcare Conference. The event is scheduled for June 10, 2022, from 9:00-9:25 am ET at the New York Marriott Marquis, Track 6. CEO Kevin S. Boyle Sr. and VP of R&D Drew Deniger, Ph.D. will present. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. Alaunos focuses on oncology cell therapies utilizing proprietary T-cell receptor technology, collaborating with leading institutes like MD Anderson and the National Cancer Institute.
Details
News Market Reaction – TCRT
The recorded move for TCRT in the trading session of this news was -8.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will present at the upcoming Jefferies Healthcare Conference being held on June 8-10, 2022, in New York, NY.
Details for the presentation are below:
Event: Jefferies 2022 Global Healthcare Conference
Date: Friday, June 10, 2022
Time: 9:00-9:25 am ET
Location: New York Marriott Marquis
Room: Track 6
A live webcast of the presentation will be accessible on the Company’s website in the Investors section under Events & Presentations at www.alaunos.com or by using the link here. A replay of the webcast will be available on the Alaunos website for approximately 90 days following the presentation.
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.